Pfizer Inc. (NYSE:PFE) Shares Sold by Revolve Wealth Partners LLC

Revolve Wealth Partners LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 12.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,460 shares of the biopharmaceutical company’s stock after selling 2,306 shares during the period. Revolve Wealth Partners LLC’s holdings in Pfizer were worth $417,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer in the fourth quarter valued at approximately $30,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE:PFE opened at $23.36 on Friday. The company’s fifty day moving average is $22.95 and its two-hundred day moving average is $25.00. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a market cap of $132.81 billion, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the business earned $0.82 EPS. The company’s revenue was down 7.8% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.36%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.